Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00664625 · ClinicalTrials.gov registry record · Phase 1
A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects
A Phase 1 study of Chronic Hepatitis C, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 6
- Study locations
NCT00664625 is a Phase 1 study of Chronic Hepatitis C that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 24 participants, below the 213-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (89% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT00664625, a Phase 1 study of Chronic Hepatitis C, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 6
- Study locations
Study Summary
The primary purpose of this study is to evaluate the safety profile and tolerability of single oral doses of BMS-791325 in subjects with chronic hepatitis C infection
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BMS-791325
Study Locations (6)
California
- Advanced Clinical Res Inst - Anaheim
- West Coast Clinical Trials, Llc - Cypress
Missouri
- Washington University School Of Medicine - St Louis
Pennsylvania
- University Of Pennsylvania - Philadelphia
Texas
- Alamo Medical Research - San Antonio
Buenos Aires
- Local Institution - Buenos Aires
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00664625
The ClinicalTrials.gov registry entry for NCT00664625 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 213-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (89% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00664625 reports 6 study locations spanning 5 distinct geographic areas - top geographies include California, Missouri, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00664625 about?
NCT00664625 is a clinical study titled "A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects". The primary purpose of this study is to evaluate the safety profile and tolerability of single oral doses of BMS-791325 in subjects with chronic hepatitis C infection
What is the current status of trial NCT00664625?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2008-05. Estimated completion is 2009-06.
What conditions does trial NCT00664625 study?
This clinical trial studies the following conditions: Chronic Hepatitis C.
What interventions are being tested in trial NCT00664625?
The interventions under investigation include: Placebo (DRUG), BMS-791325 (DRUG).
Who is sponsoring clinical trial NCT00664625?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00664625 being conducted?
This trial has 6 study locations across California, Missouri, Pennsylvania, Texas, Buenos Aires. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects
COMPLETED · Phase 1
-
Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance
COMPLETED · Phase 1
-
A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects
COMPLETED · Phase 1
-
Q-Trial in Patients With Hepatitis C
COMPLETED · Phase 1
-
Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV
COMPLETED
-
Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.